JP2009501776A - 遊離脂肪酸に起因した障害におけるチアゾール誘導体およびアナログの使用 - Google Patents

遊離脂肪酸に起因した障害におけるチアゾール誘導体およびアナログの使用 Download PDF

Info

Publication number
JP2009501776A
JP2009501776A JP2008522065A JP2008522065A JP2009501776A JP 2009501776 A JP2009501776 A JP 2009501776A JP 2008522065 A JP2008522065 A JP 2008522065A JP 2008522065 A JP2008522065 A JP 2008522065A JP 2009501776 A JP2009501776 A JP 2009501776A
Authority
JP
Japan
Prior art keywords
compound
formula
benzyl
title compound
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008522065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009501776A5 (enExample
Inventor
ヤコブ、ベストマン
ビヨルン、エリクソン
グイド、クルツ
クリスチアン、ヘドベリ
Original Assignee
ベタゲノン・エイビー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベタゲノン・エイビー filed Critical ベタゲノン・エイビー
Publication of JP2009501776A publication Critical patent/JP2009501776A/ja
Publication of JP2009501776A5 publication Critical patent/JP2009501776A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2008522065A 2005-07-21 2006-07-21 遊離脂肪酸に起因した障害におけるチアゾール誘導体およびアナログの使用 Withdrawn JP2009501776A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59562005P 2005-07-21 2005-07-21
SE0501721 2005-07-21
US74442206P 2006-04-07 2006-04-07
PCT/GB2006/002743 WO2007010281A2 (en) 2005-07-21 2006-07-21 Use of thiazole derivatives and analogues in disorders caused by free fatty acids

Publications (2)

Publication Number Publication Date
JP2009501776A true JP2009501776A (ja) 2009-01-22
JP2009501776A5 JP2009501776A5 (enExample) 2009-09-10

Family

ID=37669179

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008522065A Withdrawn JP2009501776A (ja) 2005-07-21 2006-07-21 遊離脂肪酸に起因した障害におけるチアゾール誘導体およびアナログの使用
JP2008522062A Withdrawn JP2009501775A (ja) 2005-07-21 2006-07-21 癌治療におけるチアゾール誘導体およびアナログの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008522062A Withdrawn JP2009501775A (ja) 2005-07-21 2006-07-21 癌治療におけるチアゾール誘導体およびアナログの使用

Country Status (10)

Country Link
US (2) US20090156644A1 (enExample)
EP (2) EP1906956A2 (enExample)
JP (2) JP2009501776A (enExample)
KR (2) KR20080034436A (enExample)
AU (2) AU2006271375A1 (enExample)
CA (2) CA2614327A1 (enExample)
EA (2) EA200800302A1 (enExample)
IL (2) IL188031A0 (enExample)
NO (2) NO20076333L (enExample)
WO (2) WO2007010273A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005024012A1 (de) * 2005-05-20 2006-11-23 Grünenthal GmbH Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln
WO2008065409A2 (en) * 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
WO2008090327A1 (en) * 2007-01-22 2008-07-31 Betagenon Ab New combination for use in the treatment of cancer
US20080234332A1 (en) * 2007-03-20 2008-09-25 Xiong Cai Raf kinase inhibitors containing a zinc binding moiety
CN101274918A (zh) * 2007-03-30 2008-10-01 中国科学院上海药物研究所 一类取代五元杂环化合物,其制备方法和医学用途
AR067769A1 (es) * 2007-08-03 2009-10-21 Betagenon Ab Derivado de ditiazol para el tratamiento del cancer
KR20100090250A (ko) 2007-10-09 2010-08-13 메르크 파텐트 게엠베하 글루코키나제 활성체로서 유용한 피리딘 유도체
CA2743756A1 (en) * 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
KR100998572B1 (ko) * 2007-12-14 2010-12-07 한국생명공학연구원 단백질 포스파타제의 활성을 억제하는 페닐아미노티아졸론유도체 또는 이의 약학적으로 허용가능한 염을유효성분으로 함유하는 암 예방 및 치료용 조성물
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
AU2010270030B2 (en) 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
WO2011079036A1 (en) * 2009-12-22 2011-06-30 The Translational Genomics Research Institute Benzamide derivatives
WO2012118935A1 (en) 2011-03-03 2012-09-07 Proteotech Inc Compounds for the treatment of neurodegenerative diseases
EP2760856B1 (en) * 2011-09-30 2016-09-14 Bristol-Myers Squibb Company Selective nr2b antagonists
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
CN104059060B (zh) * 2014-05-30 2017-08-01 西安交通大学 一种5‑(1h‑吲哚‑3‑亚甲基)‑1,3‑噻唑烷‑4‑酮类衍生物及其合成方法和应用
BR112022002815A2 (pt) * 2019-08-15 2022-05-10 Bayer Ag Método para preparar 2-(fenilimino)-3-alquil-1,3-tiazolidin- 4-onas
GB202112529D0 (en) * 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
EP4448492B1 (en) 2021-12-17 2026-03-04 Reglagene, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
JP7894535B2 (ja) 2023-02-28 2026-07-23 レグラジーン、インコーポレイテッド 健康状態の治療のための小分子を作製および使用するための組成物および方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3345374A (en) * 1962-09-04 1967-10-03 Bayer Ag Certain oxathiazole and dithiazole derivatives
US3671537A (en) * 1969-06-05 1972-06-20 Gyogyszerkutato Intezet Certain 3-(2,6-dichlorophenyl)-2-iminothiazolidines
US4103018A (en) * 1976-10-12 1978-07-25 Schering Corporation 2-[4-(Polyhalo-2-hydroxy-2-propyl)anilino]-2-oxazolin-4-ones and thiazolin-4-ones corresponding thereto
HU191408B (en) * 1984-04-25 1987-02-27 Egis Gyogyszergyar,Hu Process for preparing new imino-thiazolidine derivatives
DD246541A1 (de) * 1986-01-27 1987-06-10 Univ Halle Wittenberg Verfahren zur herstellung von 5-arylidenthiazolidin-4-onen
DD270072A1 (de) * 1988-03-14 1989-07-19 Univ Halle Wittenberg Verfahren zur herstellung von 5-aryliden- hoch 2-thiazolin-4-onen
US6353006B1 (en) * 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
US20040152667A1 (en) * 2002-10-23 2004-08-05 Hauske James R. 4-Alkenylthiazoles comprising epoxide functionality, and methods of use thereof
WO2005082363A1 (en) * 2004-02-20 2005-09-09 Board Of Regents, The University Of Texas System Thiazolone compounds for treatment of cancer
CN1972937A (zh) * 2004-04-30 2007-05-30 先灵公司 神经肽受体调节剂
RU2007103709A (ru) * 2004-07-01 2008-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Тиазолинонхинолины
EP1776112A4 (en) * 2004-08-10 2009-11-25 Exelixis Inc HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS
WO2006040050A1 (en) * 2004-10-14 2006-04-20 F.Hoffmann-La Roche Ag Quinazolinylmethylene thiazolinones as cdk1 inhibitors
CN100525929C (zh) * 2005-04-20 2009-08-12 郭文礼 喷水枪出水控制装置
CA2614098A1 (en) * 2005-07-04 2007-01-11 Dr. Reddy's Laboratories Ltd. Thiazoles derivatives as ampk activator

Also Published As

Publication number Publication date
NO20076333L (no) 2008-04-01
CA2615752A1 (en) 2007-01-25
AU2006271375A1 (en) 2007-01-25
EP1906955A2 (en) 2008-04-09
JP2009501775A (ja) 2009-01-22
US20090156644A1 (en) 2009-06-18
EA200800303A1 (ru) 2008-10-30
AU2006271375A2 (en) 2007-01-25
WO2007010281A2 (en) 2007-01-25
KR20080032096A (ko) 2008-04-14
US20090136472A1 (en) 2009-05-28
EA200800302A1 (ru) 2008-08-29
IL188031A0 (en) 2011-08-01
WO2007010273A3 (en) 2007-05-10
WO2007010273A2 (en) 2007-01-25
WO2007010281A3 (en) 2007-06-07
NO20076420L (no) 2008-04-09
EP1906956A2 (en) 2008-04-09
IL188163A0 (en) 2008-03-20
AU2006271383A1 (en) 2007-01-25
CA2614327A1 (en) 2007-01-25
KR20080034436A (ko) 2008-04-21

Similar Documents

Publication Publication Date Title
US20090136472A1 (en) Use of thiazole derivatives and analogues in disorders caused by free fatty acids
US8338615B2 (en) Human protein tyrosine phosphatase inhibitors and methods of use
US12209071B2 (en) Triazine derivatives for treating diseases relating to neurotrophins
AU754488B2 (en) Method for treating diabetes employing an aP2 inhibitor and combination
CA2890554A1 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
US20110177046A1 (en) Dithiazolidine and thiazolidine derivatives as anticancer agents
WO2008090356A1 (en) Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
WO2021028810A1 (en) Sulfinic acid compounds as free fatty acid receptor agonists
WO2008065409A2 (en) Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
CN101237866A (zh) 噻唑类衍生物和类似物在游离脂肪酸引起的疾病中的应用
WO2013108026A1 (en) Thiadiazolone derivatives useful in the treatment of diabetes
MX2008000973A (en) Use of thiazole derivatives and analogues in disorders caused by free fatty acids
RU2435763C2 (ru) Ингибиторы тирозинфосфатазы белка человека и способы применения
BRPI0613624A2 (pt) uso de um composto ou um sal ou solvato farmaceuticamente aceitável, ou um derivado farmaceuticamente funcional do mesmo, composto ou um sal ou solvato farmaceuticamente aceitável, ou um derivado funcional do mesmo, formulação farmacêutica, produto combinado, e, métodos de varredura para inibidores de proliferação celular induzida por ácido graxo livre, e para co-estimuladores de proliferação celular induzida por ácido graxo livre
EP3027605B1 (en) Novel indazole compounds and a process for the preparation thereof
HK1045121A1 (en) Remedies for diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090721

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100823